922 related articles for article (PubMed ID: 33730899)
1. Impact of COVID-19-related care disruptions on cervical cancer screening in the United States.
Burger EA; Jansen EE; Killen J; Kok IM; Smith MA; Sy S; Dunnewind N; G Campos N; Haas JS; Kobrin S; Kamineni A; Canfell K; Kim JJ
J Med Screen; 2021 Jun; 28(2):213-216. PubMed ID: 33730899
[TBL] [Abstract][Full Text] [Related]
2. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
Kim JJ; Burger EA; Regan C; Sy S
JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882
[TBL] [Abstract][Full Text] [Related]
3. A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions.
Burger EA; de Kok IMCM; O'Mahony JF; Rebolj M; Jansen EEL; de Bondt DD; Killen J; Hanley SJ; Castanon A; Regan MC; Kim JJ; Canfell K; Smith MA
Elife; 2022 Oct; 11():. PubMed ID: 36222673
[TBL] [Abstract][Full Text] [Related]
4. Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies.
Liang LA; Einzmann T; Franzen A; Schwarzer K; Schauberger G; Schriefer D; Radde K; Zeissig SR; Ikenberg H; Meijer CJLM; Kirkpatrick CJ; Kölbl H; Blettner M; Klug SJ
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):474-484. PubMed ID: 33187968
[TBL] [Abstract][Full Text] [Related]
5. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Melnikow J; Henderson JT; Burda BU; Senger CA; Durbin S; Weyrich MS
JAMA; 2018 Aug; 320(7):687-705. PubMed ID: 30140883
[TBL] [Abstract][Full Text] [Related]
6. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
7. Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses.
Castanon A; Rebolj M; Pesola F; Sasieni P
Br J Cancer; 2021 Apr; 124(8):1361-1365. PubMed ID: 33558708
[TBL] [Abstract][Full Text] [Related]
8. Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.
Smith MA; Burger EA; Castanon A; de Kok IMCM; Hanley SJB; Rebolj M; Hall MT; Jansen EEL; Killen J; O'Farrell X; Kim JJ; Canfell K
Prev Med; 2021 Oct; 151():106623. PubMed ID: 34029578
[TBL] [Abstract][Full Text] [Related]
9. The impact of the COVID-19 pandemic on the Ontario Cervical Screening Program, colposcopy and treatment services in Ontario, Canada: a population-based study.
Meggetto O; Jembere N; Gao J; Walker MJ; Rey M; Rabeneck L; Murphy KJ; Kupets R;
BJOG; 2021 Aug; 128(9):1503-1510. PubMed ID: 33982870
[TBL] [Abstract][Full Text] [Related]
10. Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination.
Grimes DR; Corry EMA; Malagón T; O'Riain C; Franco EL; Brennan DJ
JAMA Netw Open; 2021 Jun; 4(6):e2115321. PubMed ID: 34190993
[TBL] [Abstract][Full Text] [Related]
11. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing.
Fokom Domgue J; Cunningham SA; Yu RK; Shete S
Ann Epidemiol; 2019 Aug; 36():40-47. PubMed ID: 31320153
[TBL] [Abstract][Full Text] [Related]
13. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
14. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force.
Kulasingam SL; Havrilesky LJ; Ghebre R; Myers ER
J Low Genit Tract Dis; 2013 Apr; 17(2):193-202. PubMed ID: 23519288
[TBL] [Abstract][Full Text] [Related]
15. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
Cox JT;
Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
[TBL] [Abstract][Full Text] [Related]
16. Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples.
Leung SOA; Feldman S; Kalyanaraman R; Shanmugam V; Worley MJ; Berkowitz RS; Horowitz NS; Feltmate CM; Muto MG; Lee LJ; King MT; Einarsson JI; Ajao MO; Elias KM
Am J Reprod Immunol; 2021 Jul; 86(1):e13394. PubMed ID: 33501727
[TBL] [Abstract][Full Text] [Related]
17. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.
; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2018 Aug; 320(7):674-686. PubMed ID: 30140884
[TBL] [Abstract][Full Text] [Related]
18. Negative Roche cobas HPV testing in cases of biopsy-proven invasive cervical carcinoma, compared with Hybrid Capture 2 and liquid-based cytology.
Vasilyeva D; Tiscornia-Wasserman P; Gonzalez AA
J Am Soc Cytopathol; 2021; 10(2):128-134. PubMed ID: 32896510
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
